Molecular Partners Management
Management criteria checks 3/4
Molecular Partners' CEO is Patrick Amstutz, appointed in Jan 2004, has a tenure of 21.33 years. total yearly compensation is CHF1.10M, comprised of 35.2% salary and 64.8% bonuses, including company stock and options. directly owns 2.03% of the company’s shares, worth $3.15M. The average tenure of the management team and the board of directors is 3.8 years and 5.1 years respectively.
Key information
Patrick Amstutz
Chief executive officer
CHF 1.1m
Total compensation
| CEO salary percentage | 35.2% |
| CEO tenure | 21.3yrs |
| CEO ownership | 2.0% |
| Management average tenure | 3.8yrs |
| Board average tenure | 5.1yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | CHF 1m | CHF 385k | -CHF 54m |
| Sep 30 2024 | n/a | n/a | -CHF 63m |
| Jun 30 2024 | n/a | n/a | -CHF 58m |
| Mar 31 2024 | n/a | n/a | -CHF 59m |
| Dec 31 2023 | CHF 1m | CHF 385k | -CHF 62m |
| Sep 30 2023 | n/a | n/a | -CHF 60m |
| Jun 30 2023 | n/a | n/a | -CHF 62m |
| Mar 31 2023 | n/a | n/a | -CHF 50m |
| Dec 31 2022 | CHF 1m | CHF 383k | CHF 118m |
| Sep 30 2022 | n/a | n/a | CHF 117m |
| Jun 30 2022 | n/a | n/a | CHF 118m |
| Mar 31 2022 | n/a | n/a | CHF 106m |
| Dec 31 2021 | CHF 1m | CHF 380k | -CHF 64m |
| Sep 30 2021 | n/a | n/a | -CHF 67m |
| Jun 30 2021 | n/a | n/a | -CHF 72m |
| Mar 31 2021 | n/a | n/a | -CHF 66m |
| Dec 31 2020 | CHF 1m | CHF 380k | -CHF 63m |
| Sep 30 2020 | n/a | n/a | -CHF 53m |
| Jun 30 2020 | n/a | n/a | -CHF 48m |
| Mar 31 2020 | n/a | n/a | -CHF 43m |
| Dec 31 2019 | CHF 930k | CHF 363k | -CHF 36m |
| Sep 30 2019 | n/a | n/a | -CHF 37m |
| Jun 30 2019 | n/a | n/a | -CHF 38m |
| Mar 31 2019 | n/a | n/a | -CHF 38m |
| Dec 31 2018 | CHF 909k | CHF 346k | -CHF 37m |
Compensation vs Market: Patrick's total compensation ($USD1.33M) is about average for companies of similar size in the US market ($USD1.59M).
Compensation vs Earnings: Patrick's compensation has increased whilst the company is unprofitable.
CEO
Patrick Amstutz (49 yo)
21.3yrs
Tenure
CHF 1,095,000
Compensation
Dr. Patrick Amstutz, Ph.D. is a Co-Founder of Molecular Partners AG and has been its Chief Executive Officer since November 2016 and serves as its Member of Management Board since 2004. Dr. Amstutz serves...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 21.3yrs | CHF 1.10m | 2.03% $ 3.2m | |
| Co-Founder | 21.3yrs | no data | 1.94% $ 3.0m | |
| Senior VP of Finance | 5.8yrs | no data | no data | |
| COO & Member of Management Board | 2.8yrs | no data | 0.078% $ 121.0k | |
| Executive VP of People & Community and Member of Management Board | 3.4yrs | no data | 0.071% $ 110.3k | |
| Chief Medical Officer & Member of the Management Board | less than a year | no data | 0.059% $ 92.1k | |
| Senior Vice President of Research & Technology | 4.2yrs | no data | no data | |
| Senior Vice President of Investor Relations | no data | no data | no data | |
| General Counsel | 2.5yrs | no data | no data | |
| Strategic Consultant | 5.8yrs | no data | no data | |
| Senior Vice President of Research & Early Development | 3.3yrs | no data | no data |
3.8yrs
Average Tenure
53yo
Average Age
Experienced Management: MOLN's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 7.6yrs | CHF 1.10m | 2.03% $ 3.2m | |
| Independent Non Executive Director | 11yrs | CHF 135.00k | 0.047% $ 72.9k | |
| Independent Chairman of the Board | 7.6yrs | CHF 295.00k | 0.091% $ 141.4k | |
| Independent Director | 5.1yrs | CHF 125.00k | 0.016% $ 25.6k | |
| Independent Director | 4.1yrs | CHF 133.00k | 0.0069% $ 10.8k | |
| Independent Director | 5.1yrs | CHF 135.00k | 0.016% $ 25.6k | |
| Independent Director | 5.1yrs | CHF 130.00k | 0.016% $ 25.6k | |
| Independent Director | 4.1yrs | CHF 135.00k | 0.0062% $ 9.6k |
5.1yrs
Average Tenure
59yo
Average Age
Experienced Board: MOLN's board of directors are considered experienced (5.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/06 10:12 |
| End of Day Share Price | 2025/05/06 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Molecular Partners AG is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jo Walton | Credit Suisse |
| null null | Credit Suisse |
| Thomas Kaufmann | Credit Suisse |